Drug Trial Radar · NCT07673627
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Jul 10, 2026
Primary completion
Oct 2027
Study completion Apr 2028
Sponsor
- Lead sponsor
- argenxargenx (ARGX)
- Sponsor type
- Industry
- First posted
- Jun 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life. The aim of this ISA2 is to investigate the effects of empasiprubart in participants with AChR-Ab seropositive generalized myasthenia gravis (gMG). The ADAPT Forward master protocol is registered on https://clinicaltrials.gov/study/NCT07294170 More information can be found here: https://clinicaltrials.argenx.com/adaptforward2
Conditions
- AChR-Ab Seropositive Generalized Myasthenia Gravis
- Myasthenia Gravis (MG)
- MG - Myasthenia Gravis
- gMG
Interventions
Empasiprubart IVBiological
Intravenous infusions of empasiprubart
Placebo IVOther
Intravenous infusions of placebo
Efgartigimod PH20 SC PFSCombination product
Subcutaneous administration of efgartigimod PH20 via pre-filled syringe (PFS)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events and serious adverse events in the DBTPTime frame: Up to 12 weeks
Locations
19 sites in 7 countries. Site status is shown where the registry gives one.
Neurology Center of Southern California
Carlsbad, California · Recruiting
Visionary Investigators Network
Miami, Florida · Recruiting
University of South Florida Health
Tampa, Florida · Recruiting
Profound Research LLC at Las Vegas Neurology Center
Las Vegas, Nevada · Recruiting
Dent Neurologic Institute - Amherst
Amherst, New York · Recruiting
Erlanger Health System
Chattanooga, Tennessee · Recruiting
National Neuromuscular Research Institute
Austin, Texas · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
Eginitio Hospital
Athens, Greece · Recruiting
AHEPA University General Hospital of Thessaloniki
Thessaloniki, Thessaloniki, Greece · Recruiting
Ospedale Papa Giovanni XXIII
Bergamo, Italy · Recruiting
Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan, Italy · Recruiting
Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italy · Recruiting
Azienda Ospedaliero-Universitaria Sant'Andrea
Roma, Italy · Recruiting
General Hanamaki Hospital
Hanamaki, Japan · Recruiting
National Hospital Organization Sendai Medical Center
Sendai, Japan · Recruiting
Leids Universitair Medisch Centrum
Leiden, Netherlands · Recruiting
Hospital de La Santa Creu i Sant Pau
Barcelona, Spain · Recruiting
Hospital Regional Universitario de Malaga - Hospital General
Málaga, Malaga, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.